Reprogenesis became a public company through its merger in July 2000 with Creative Biomolecules and Ontogeny. Curis, the product of the three-way combination, initially focused on regenerative medicine, but has evolved to become a leader in targeting signaling pathways – especially those involved in different cancers. The company’s so-called Hedgehog pathway inhibitor vismodegib is now being marketed in collaboration with Genentech.